NCT03417570

Brief Summary

The hypothesis is that the addition of a transparent cap to the end of the endoscope will increase the detection and diagnostic yield of visible lesions in Barrett's esophagus. Thus, the goal of this tandem design trial is to compare the diagnostic yield (DY) of cap assisted endoscopy with that of conventional endoscopy using high definition-white light endoscopy (HD-WLE) and narrow band imaging (NBI) in patients with Barrett's esophagus.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 22, 2017

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 25, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 31, 2018

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2021

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 17, 2021

Completed
8 months until next milestone

Results Posted

Study results publicly available

July 29, 2022

Completed
Last Updated

September 1, 2022

Status Verified

August 1, 2022

Enrollment Period

3.9 years

First QC Date

January 25, 2018

Results QC Date

June 2, 2022

Last Update Submit

August 1, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants Who Had a Diagnostic Yield Obtained

    -Diagnostic yield is defined as Barrett's esophagus lesions that were identified and confirmed histologically as low grade dysplasia, high grade dysplasia, intramucosal cancer, or invasive adenocarcinoma

    At the time of procedure (day 1)

Secondary Outcomes (4)

  • Number of Participants With Visible Lesions in EGD With Cap Versus Without Cap

    At the time of procedure (day 1)

  • Number of Participants With High Grade Dysplasia or Esophageal Adenocarcinoma

    At the time of procedure (day 1)

  • Total Procedure Duration in Seconds

    At the time of procedure (day 1)

  • Safety as Measured by Number of Participants With Procedure-related Adverse Events

    Through 48 hours after EGD

Study Arms (2)

Arm 1: EGD with cap first, followed by EGD without cap

EXPERIMENTAL

-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap in the same procedural period.

Procedure: Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)Device: Olympus Disposable Distal Attachment Cap

Arm 2: EGD without cap first, followed by EGD with cap

EXPERIMENTAL

-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap in the same procedural period.

Procedure: Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)Device: Olympus Disposable Distal Attachment Cap

Interventions

-The second endoscopist will be blinded to the results of the initial exam.

Also known as: EGD
Arm 1: EGD with cap first, followed by EGD without capArm 2: EGD without cap first, followed by EGD with cap

-The second endoscopist will be blinded to the results of the initial exam.

Also known as: Cap
Arm 1: EGD with cap first, followed by EGD without capArm 2: EGD without cap first, followed by EGD with cap

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Must be at least 18 years of age.
  • Must be patients undergoing standard of care EGD for the confirmation of dysplasia in BE or EET for dysplasia in BE.
  • Must be able to understand and willing to sign an IRB-approved written informed consent document.

You may not qualify if:

  • Pregnant or breastfeeding.
  • Prior endoscopic treatment for BE.
  • Unable to tolerate sedation due to medical comorbidities.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Related Links

MeSH Terms

Conditions

Barrett Esophagus

Interventions

Endoscopy, Digestive SystemNarrow Band ImagingContraceptive Devices, Female

Condition Hierarchy (Ancestors)

Precancerous ConditionsNeoplasmsEsophageal DiseasesGastrointestinal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, Digestive SystemDiagnostic Techniques and ProceduresDiagnosisEndoscopyDiagnostic Techniques, SurgicalDigestive System Surgical ProceduresSurgical Procedures, OperativeMinimally Invasive Surgical ProceduresOptical ImagingDiagnostic ImagingInvestigative TechniquesContraceptive DevicesEquipment and Supplies

Results Point of Contact

Title
Vladimir M. Kushnir, M.D.
Organization
Washington University School of Medicine

Study Officials

  • Vladimir M Kushnir, M.D.

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 25, 2018

First Posted

January 31, 2018

Study Start

December 22, 2017

Primary Completion

November 15, 2021

Study Completion

November 17, 2021

Last Updated

September 1, 2022

Results First Posted

July 29, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations